TrialInternational journal of hematology2019

Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.

Naohito Fujishima et al.PubMed ↗Publisher ↗

No numbers read from the abstract.